Adalta Ltd has released a press release.
AD-214 Phase I extension clinical study - interim results
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- AdAlta closes oversubscribed $1.65 million raise
- Oversubscribed placement result
- Placement to raise up to $1.23million
- AD-214 well tolerated in Phase I extension study
- R&D tax refund received & R&D Loan repayment terms extended
Later from AdAlta
- Chair address and CEO presentation to AGM
- New malaria inhibiting i-body
- January 2024 partnering presentations and progress
- Positive AD-214 Phase I extension study results
- Corporate Presentation
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta